{"id":39206,"date":"2025-08-13T12:52:32","date_gmt":"2025-08-13T04:52:32","guid":{"rendered":"https:\/\/flcube.com\/?p=39206"},"modified":"2025-08-13T12:52:33","modified_gmt":"2025-08-13T04:52:33","slug":"sino-biopharmaceuticals-tqb3142-ind-application-accepted-by-chinas-nmpa-for-malignant-tumor-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39206","title":{"rendered":"Sino Biopharmaceutical’s TQB3142 IND Application Accepted by China’s NMPA for Malignant Tumor Treatment"},"content":{"rendered":"\n

Sino Biopharmaceutical Limited (HKG: 1177<\/a>) announced that the Investigational New Drug (IND) application for TQB3142, its independently developed innovative drug for the treatment of malignant tumors, has been accepted by China’s National Medical Products Administration (NMPA). This marks a significant step forward in the company’s oncology pipeline.<\/p>\n\n\n\n

Drug Mechanism<\/strong>
TQB3142 is a PROTAC molecule designed to specifically target and degrade the Bcl-xL protein via the ubiquitin-proteasome system. By reducing Bcl-xL protein levels, TQB3142 aims to suppress the protein’s inhibitory effect on tumor apoptosis, thereby activating the Caspase cascade response and inducing apoptosis in tumor cells. This mechanism offers a novel approach to treating malignant tumors by directly targeting apoptosis regulation.<\/p>\n\n\n\n

Preclinical Findings<\/strong>
Preclinical studies have demonstrated that TQB3142 exhibits significant antitumor activity across multiple transplanted tumor models. Notably, TQB3142 has shown a lower risk of platelet toxicity compared to other drug candidates in its class. This characteristic contributes to a more favorable therapeutic window and manageable metabolic risks, positioning TQB3142 as a promising therapeutic option with a favorable safety profile.-Fineline Info & Tech<\/a><\/p>\n\n\n\n